Biomea Fusion (BMEA) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($104.2 million vs $96.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | PLYX |
|---|---|---|
| Share price | $1.33 | $2.09 |
| Market cap | $96.16M | $104.18M |
| 1-day change | +0.76% | 0.00% |
| YTD return | +6.45% | — |
| 1-year return | -28.46% | — |
| 5-year return | -88.65% | — |
| EPS (TTM) | $-0.29 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $48.91 |
| 52-week low | $0.872 | $1.85 |
| Distance from 52-week high | -40.55% | -95.73% |
| Average volume | 1.47M | 75.60K |
| Shares outstanding | 72.30M | 49.85M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BMEA vs PLYX FAQ
Which is bigger, Biomea Fusion or Polaryx Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $104.18M compared with $96.16M for Biomea Fusion (BMEA).
Are Biomea Fusion and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.